The Corporate Sustainability Reporting Directive landed in most pharma and biotech organisations as a compliance project. A new set of disclosures. A reporting framework — the European Sustainability Reporting Standards — to be mapped against existing data. A sustainability team mandate. The conversation is almost entirely happening in corporate affairs, ESG, and investor relations.
That framing is structurally incomplete. CSRD is not only a disclosure obligation — it is a framework that makes access, affordability, and pricing policies publicly legible in a standardised format that institutional investors, payers, and governments will use. The organisations treating it as a reporting problem are building a disclosure architecture without understanding what they are disclosing — and to whom, and with what strategic consequence.
What CSRD actually requires on access and affordability
The European Sustainability Reporting Standard S4 — Consumer and End-User Interests — requires companies to report on whether and how they ensure access to their products for all relevant segments of the population, including at-risk and underserved groups. For pharma and biotech, this is not an abstract social reporting category. It is a direct question about pricing policy, reimbursement strategy, and the gap between list price and accessible price across the markets in which a product is sold.
"CSRD turns access policy from a private commercial decision into a public disclosure. Payers, investors, and governments will read it. Most access teams don't know it's being written."
ESRS E1 and S1 create further intersections: climate-related disclosures on manufacturing and supply chain, and workforce disclosures that include healthcare access for employee populations. For an integrated life sciences company, the sustainability reporting framework touches every major commercial function — and most of those functions are not in the room when CSRD compliance strategies are being designed.
The payer dimension
European payers are beginning to incorporate CSRD disclosures into their assessment frameworks. The reasoning is straightforward: if a company is publicly disclosing that it ensures equitable access to its products, that disclosure creates an expectation that payers can reference in reimbursement negotiations. A company that reports a high access commitment under ESRS S4 and subsequently submits a reimbursement dossier at a price that limits patient access has created a compliance gap that payers and patient advocacy groups can exploit.
Where CSRD Intersects with Commercial Access Decisions
The most significant payer implication is not the immediate reporting cycle — it is the precedent-setting nature of first disclosures. What a company reports in its first CSRD cycle becomes the baseline against which future performance is measured. Payers and institutional investors will track the trajectory. Access commitments made in year one that cannot be sustained in year three create a different problem than not making them at all.
The investor dimension
Institutional investors are using CSRD disclosures to score pharmaceutical companies on access and affordability as part of ESG assessment. The Access to Medicine Foundation framework, which major institutional investors reference, explicitly assesses whether companies have public commitments to equitable access and whether their pricing and reimbursement strategies are consistent with those commitments. CSRD standardises and mandates the disclosure that investors previously had to infer from voluntary reporting.
The access team isn't writing the CSRD disclosure
In most large pharma and biotech companies, CSRD compliance is being led by corporate sustainability teams with input from legal, finance, and investor relations. The commercial access function — the team that knows what the pricing policies actually are, what the managed entry agreement terms look like, what the real-world access gaps are — is typically not involved. This means the disclosures being written may not accurately reflect the commercial reality they are supposed to describe. And when payers and investors probe the gap, it is the access team that will need to explain it.
What access teams need to do now
The window to shape CSRD disclosures before first reporting cycles is narrow. For companies in the first reporting cohort — large EU-listed companies with first mandatory disclosure for 2025 — that window has already partly closed. For the broader reporting population coming into scope through 2026 and 2027, it remains open — but requires access teams to proactively engage with CSRD compliance processes rather than inherit disclosures written without their input.
- Does your access function have a seat in the CSRD compliance process — or will you inherit disclosures about your policies that you had no part in drafting?
- Have you audited the gap between your ESRS S4 access commitments and your actual pricing and reimbursement outcomes across EU markets?
- Are your managed entry agreement structures and confidential pricing arrangements compatible with the disclosure obligations CSRD creates — or do they create a compliance gap you haven't yet identified?
- Have you assessed how your CSRD access disclosures will be read by the payers you will be negotiating with in the next reporting cycle?
CSRD is a sustainability reporting obligation. It is also the first standardised framework that makes pharmaceutical access and pricing policy publicly legible at scale. The organisations that treat it as a compliance exercise will disclose what they did. The organisations that treat it as a strategic tool will shape what they commit to — and build the commercial architecture to deliver it. The difference between those two postures will be visible in the disclosures, and consequential in the negotiations that follow.